Skip to main content
Download PDF

Ursolic acid-enriched kudingcha extract enhances the antitumor activity of bacteria-mediated cancer immunotherapy

BMC Complementary Medicine and Therapies volume 22, Article number: 123 (2022) Cite this article

Abstract

Background

Bacteria-mediated cancer immunotherapy (BCI) robustly stimulates the immune system and represses angiogenesis, but tumor recurrence and metastasis commonly occur after BCI. The natural product Ilex kudingcha C. J Tseng enriched with ursolic acid has anti-cancer activity and could potentially augment the therapeutic effects of BCI. The objective of the present study was to determine potential additive effects of these modalities.

Methods

We investigated the anti-cancer activity of KDCE (Kudingcha extract) combined with S.t△ppGpp in the mice colon cancer models.

Results

In the present study, KDCE combined with S.t△ppGpp BCI improved antitumor therapeutic efficacy compared to S.t△ppGpp or KDCE alone. KDCE did not prolong bacterial tumor-colonizing time, but enhanced the antiangiogenic effect of S.t△ppGpp by downregulatingVEGFR2. We speculated that KDCE-induced VEGFR2 downregulation is associated with FAK/MMP9/STAT3 axis but not AKT or ERK.

Conclusions

Ursolic acid-enriched KDCE enhances the antitumor activity of BCI, which could be mediated by VEGFR2 downregulation and subsequent suppression of angiogenesis. Therefore, combination therapy with S.t△ppGpp and KDCE is a potential cancer therapeutic strategy.

Peer Review reports

Background

Immunotherapy is the fourth-leading cancer therapy following surgery, radiotherapy, and chemotherapy [1, 2]. Immunological checkpoint therapies, such as CTLA-4, PD-L1, and PD-1, have been approved as a clinical cancer treatments [3], but also have limitations; “cold tumors” have decreased T cell infiltration and decreased antigen mutations, such as in pancreatic and ovarian cancers [4]. In addition, checkpoint therapy could cause autoimmune diseases by overactivating the immune system to attack normal tissues [5]. Bacteria-mediated cancer immunotherapy (BCI) was originally described over a century ago and has significant therapeutic advantages, including i) specific tumor targeting; ii) deep penetration of tumor tissue; iii) triggering robust antitumor immune stimulation; iv) low toxicity to normal tissues; v) lower cost than conventional immunotherapies [6].

Attenuated engineered Salmonella has been tested in recent clinical trials [7, 8]. Salmonella-mediated cancer immunotherapy profoundly affects the tumor microenvironment through several means: shifting macrophage phenotypes from M2 to M1 via toll-like receptors (TLRs) [9], initiating tumor cell apoptosis by inducing robust nitric oxide (NO) production in tumor cells [10], and inhibiting angiogenesis by downregulating vascular endothelial growth factor (VEGF) [11]. Angiogenesis has a very important role in tumor growth and metastasis. Salmonella combined with an antiangiogenic agents achieves improved therapeutic efficacy [12, 13].

Ilex kudingcha C. J Tseng is herbal tea in China, and bioactive compounds in this natural product have multiple therapeutic effects, including anticancer [14], anti-inflammatory [15], antidiabetic [16], and hypolipidaemic effects [17]. Ursolic acid is a pentacyclic triterpene acid and contributes to the anticancer activity of kudingcha [18]. Ko et al. reported that ursolic acid significantly inhibits cancer progression via phosphorylation of the ERK and AKT [19]. Prior studies also identified that ursolic acid nanoparticle-coated attenuated Salmonella typhimurium significantly suppresses tumor growth and metastasis [20].

The present study aimed to determine the combined effects of Salmonella-mediated cancer immunotherapy and ursolic acid-enriched kudingcha extracon antitumor activity in a mouse colon cancer model.

Methods

Plant material

Ilex kudingcha leaves were collected from Kudingcha Institute (Hainan University, Haikou, Hainan, China) and the state permissions were unnecessary to collect the sample. The plant material was identified by their morphological characteristics by Dr. Guomin Liu from the Kudingcha Institute, Hainan University. One voucher specimen (H. Y. Liang 60,355) was deposited at the Kudingcha Institute. Dried leaves were ground and passed through a sieve (24 mesh). Kudingcha powder (100 g) was boiled twice in water. The collected residue was extracted twice with 4 L 100% EtOH for 48 h, then subjected to ultrasound-assisted extraction at 50 °C for 30 min. The solvent was removed by rotary evaporation to yield a dry extract, which was dissolved in petroleum ether, evaporated, and freeze-dried to remove organic solvents. The petroleum ether fraction was used for further photochemical analysis and experiments.

HPLC-PDA analysis

An HPLC-PDA system (Waters Corporation, Milford, MA, USA) consisting of a Waters 600 pump and a 996 PDA detector was used. Analyses were performed using a Waters Sun-Fire C18 column (4.6 × 150 mm, 5 μm). Chromatography conditions were as follows: MeOH: H2O, 90: 10 to 40: 60 for 40 min; MeOH: H2O, 40: 60 to 100% MeOH for 1 min; and 100% MeOH for 9 min. The flow rate was 0.1 mL/min; injection volume was 20 μL kudingcha extract (20 mg/mL in petroleum ether); and detection wavelengths were 220, 254, and 280 nm.

Mouse colon cancer model and bacterial injection

BalB/c mice (male, 5–6 weeks old) were purchased from Guangdong Experimental Animal Center (Guangzhou, Guangdong, China). Experiments were supervised by the Animal Science and Technology Ethics Committee of Hainan University. Mice were anesthetized with either 2% isoflurane or ketamine (200 mg/kg). CT-26 cells (1 × 106, ATCC) cultured in DMEM with 10% FBS (Gibco, USA) were implanted subcutaneously into the right flank to generate colon cancer xenografts. Tumor-bearing mice were randomly divided into four groups (n = 9/group) as follows: PBS, SLΔppGpp, KDCE, and SLΔppGpp + KDCE. KDCE groups received 1 g/kg KDCE daily via intragastric administration. When tumor volume reached 120–160 mm3, 1 × 107 colony-forming units (CFU) SLΔppGpp bacteria were intravenously injected. When tumor volume reached ≥1500 mm3, mice were euthanized. Tumor volumes were measured and calculated using the following formula: (L × H × W)/2 (L: length; W: width; H: height).

Attenuated Salmonella typhimurium, S.t△ppGpp (defective in the synthesis of ppGpp (RelA::cat, Spot::kan)) carrying the luciferase gene Lux (S.t△ppGpp-lux; SHJ2168, 9] was kindly provided by J. J. Min (Institute for Molecular Imaging and Theranostics, Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea) and grown in Luria Bertani medium containing kanamycin (Sigma-Aldrich). Bacteria were stored in 25% glycerol stocks at − 80 °C.

Bacteria counting and optical bioluminescence imaging

Tissues, including tumor, liver, lung, and spleen, were collected from mice. Ground tissue was transferred to agar petri dishes and incubated overnight at 37 °C. The bacterial number per gram of tissue was calculated by the formula: Y × 10Z × (1 + X) × 10/X (CFU/g; X: tissue weight; Y: bacterial number on the petri dish; Z: dilution factor).

Tumor-bearing mice were injected through the tail vein with S.t△ppGpp Lux in 100 μL PBS to image bacterial bioluminescence imaging and divided into two treatment groups (n = 6/group): S.t△ppGpp Lux and S.t△ppGpp Lux + KDCE (intragastric administration 1 g/kg daily). D-luciferin (750 μg, Caliper, Hopkinton, MA, USA) was intraperitoneally injected, and bioluminescence imaging was then performed using an IVIS 100 (Caliper).

H&E staining

Liver, spleen, kidney, and lung were removed from euthanized mice and fixed in 4% PFA solution for toxicity evaluation of KDCE + S.t△ppGpp. Paraffin sections (10 μM) were stained with a Hematoxylin and Eosin Staining Kit (C0105, Beyotime) according to the manufacturer’s protocol.

Western blotting

Human Umbilical Vein Endothelial Cells (HUVECs, ATCC) were treated with KDCE (0, 40, 80, 100, 120, and 160 μg/ml) for 24 h. Protein lysates were separated by 10% SDS-PAGE and transferred to PVDF membranes (Merck, Darmstadt, Germany), which were incubated overnight at 4 °C with primary antibodies against VEGFR2 (sc-6251), p-ERK (sc-136,521), ERK1/2 (sc514302), AKT1/2/3 (sc56878), p-Akt (sc-293,125), and β-actin (sc-69,879) (Santa Cruz Biotechnology, Inc., Texas, USA). Membranes were then incubated with secondary antibodies. Protein bands were visualized using a chemiluminescence detection kit (ATTO, Tokyo, Japan) and semi-quantified using Image J Ω (Media Cybernetics, Maryland, USA).

Statistical analyses

Statistical analyses were conducted using the GraphPad Prism 5.0, and p < 0.05 was considered statistically significant. Survival analysis was conducted using the Kaplan-Meier method and a log-rank test. All data are expressed as means ± SEM.

Results

KDCE Ursolic acid content

Leaves of I. kudingcha were collected from the Kudingcha Institute, Hainan University, Hainan province, China, in July 2020. Kudingcha powder (100 g) was extracted with boiled water, 100% EtOH, and petroleum ether in turn. The yield petroleum ether fraction (7.49 g) was used to detect the concentration of ursolic acid in KDCE using spectrophotometric analysis. Results indicated that KDCE contains 134 mg/g of ursolic acid using purified standards as calibrators at 220, 254, and 280 nm (Fig. 1).

Fig. 1
figure 1

KDCE contains 134 mg/g of ursolic acid. HPLC chromatograms for ursolic acid standard solution (A) and kudingcha samples (B)

Full size image

Effect of KDCE on anticancer activity of BCI

To evaluate the effect of KDCE on the therapeutic efficacy of BCI, SLΔppGpp (3 × 107 CFU) was injected into tumor-bearing mice via the tail vein on day 1, followed by intragastric administration of KDCE (1 g/kg) daily from day 2 to day 27. KDCE had antitumor activity, and when combined with SLΔppGpp had a strong synergistic effect in suppressing tumor growth (Fig. 2A and B) and increased survival rate (Fig. 2C).

Fig. 2
figure 2

Effect of KDCE on S.t△ppGpp BCI. KDCE combined with SLΔppGpp show synergistic effect in suppressing tumor growth and increased survival rate. A Representative images of tumors for each group over time. B Tumor volume measurement (BalB/c mice, n = 9/group). C Kaplan-Meier survival curve. Statistical significance was calculated by comparison with PBS or S.t△ppGpp-alone groups (***p < 0.001)

Full size image

Effect of KDCE on tumor-colonizing bacteria

To determine the effect of KDCE on tumor-colonizing bacteria, bacterial activity was measured by bioluminescence analysis, in which tumor-bearing mice were injected with SLΔppGpp-Lux. The bacterial tumor-colonizing time in the SLΔppGpp + KDCE group (8 days) was shorter than in the SLΔppGpp-only group (10 days) (Fig. 3A).

Fig. 3
figure 3

Effect of KDCE on tumor-colonizing bacteria. The survivor and number of tumor-colonizing bacteria in the SLΔppGpp plus KDCE group was lower than in the SLΔppGpp-only group (A) Non-invasive monitoring of bacterial bioluminescence for 12 days (BalB/c mice, n = 6/group). B Bacterial counts in isolated organs from tumor-bearing mice on days 2 and 6 (BalB/c mice, n = 6/group). Statistical significance was calculated by comparison with S.t△ppGpp-alone groups (*p < 0.05, ***p < 0.001)

Full size image

Subsequently, to determine bacterial distribution in major organs, we collected tumor, lung, liver, and spleen samples from bacteria-injected tumor-bearing mice on days 2 and 6. The tumor-colonizing bacterial number in the SLΔppGpp + KDCE group was higher on day 2 but lower on day 6 compared to the SLΔppGpp-only group (Fig. 3B).

Toxicity evaluation of KDCE/BCI combination therapy

To evaluate the safety of KDCE/BCI combination therapy, we collected lung, liver, and spleen samples from SLΔppGpp-injected tumor-bearing mice on day 6 after KDCE treatment for H&E staining. SLΔppGpp + KDCE did not induce toxicity in the liver, spleen, kidney, or lung as compared to other groups (Fig. 4A) but did decrease body weight (Fig. 4B).

Fig. 4
figure 4

Toxicity evaluation of KDCE combined with S.t△ppGpp. A H&E staining for isolated organs of tumor-bearing mice on day 6 after BCI treatment (BalB/c mice, n = 6/group). No signs of steatosis, inflammatory infiltrate or fibrosis in the liver, spleen, kidney, and lung were observed in each group. B Body weight on day 27 (BalB/c mice, n = 6/group). Statistical significance was calculated by comparison with PBS or S.t△ppGpp-alone or KDCE groups (**p < 0.01)

Full size image

KDCE VEGFR2 downregulation

To determine if the anticancer activity of KDCE was related to suppression of angiogenesis, we measured AKT and ERK phosphorylation and VEGFR2 levels using western blotting in HUVECs. KDCE significantly downregulated VEGFR2 in a dose-dependent manner, but did not affect AKT or ERK phosphorylation (Fig. 5).

Fig. 5
figure 5

Effect of KDCE on protein expression of p-AKT, AKT, p-ERK, ERK, and VEGFR2. VEGFR2 was downregulated, but not p-AKT or p-ERK

Full size image

Discussions

The delivery and efficiency of the drug are improved by nano-encapsulating, but FDA approval and commercialization of nanomaterial still is a major challenge [21,22,23]. We previously observed remarkable tumor-targeting and therapeutic effects using hydrocypropyl-β-cyclodextrin (HPCD)-encapsulated ursolic acid coating the surface of S.t△ppGppand by amantadine (AMA) [20]. However, considering ursolic acid-enriched KDCE is easier to access in a clinical trial than nano-encapsulated ursolic acid, we determined the tumor therapeutic effect of KDCE combined with S.t△ppGpp.

Salmonella-mediated cancer immunotherapy stimulates immune activation and inhibits angiogenesis by downregulating VEGF [11]; Kudingcha [24] and ursolic acid induces cancer cell apoptosis [25]. Here, we demonstrated that ursolic acid-enriched KDCE enhances the antitumor activity of S.t ΔppGpp-mediated cancer immunotherapy, but does not increase bacterial tumor-colonizing time or number. We postulated that ursolic acid-enriched KDCE could decrease tumor volume by downregulating VEGFR2, limiting bacterial colonization. Several prior studies reported that VEGFR2 downregulation plays important role in suppressing tumor angiogenesis, which is related to suppression of ERK [26,27,28] and AKT [29,30,31]. However, our findings suggest that KDCE-induced VEGFR2 downregulation is not related to deactivation of the AKT or ERK pathways. The prior studies reported that VEGFR2 downregulation must be due to decreased VEGF synthesis, which auto-regulates its receptor, VEGFR2. In addition, the phosphorylation FAK and Matrix metalloproteinases 9 (MMP9) and Signal transducer and activator of transcription 3 (STAT3) interact with VEGF signaling [32, 33]. Hence, we speculated that perhaps KDCE-induced VEGFR2 downregulation is associated with FAK/MMP9/STAT3 axis.

The current research has been focused on bacteria-mediated gene therapy of delivering therapeutic drugs for enhancing the efficacy of BCI [34,35,36], but our investigation indicated that a combination of BCI and nature products having anti-angiogenesis function is also an alternative approach.

Conclusions

The present study demonstrated that ursolic acid-enriched KDCE enhances the antitumor activity of BCI, which could be mediated by VEGFR2 downregulation and subsequent suppression of angiogenesis. Combined BCI and KDCE treatment is a potential modality for cancer therapy.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Abbreviations

BCI:

Bacteria-mediated cancer immunotherapy

KDCE:

Kudingcha extract

TLRs:

Toll-like receptors

VEGF:

Vascular endothelial growth factor

VEGFR2:

Vascular endothelial growth factor receptor 2

S.t△ppGpp:

Attenuated Salmonella typhimurium

ERK:

Extracellular Regulated protein Kinases

AKT:

Protein Kinase B

HPCD:

Hydrocypropyl-β-cyclodextrin

AMA:

Amantadine

MMP9:

Matrix metalloproteinases 9)

STAT3:

Signal transducer and activator of transcription 3

References

  1. Ciardiello D, Vitiello PP, Cardone C, Martini G, Troiani T, Martinelli E, et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat Rev. 2019;76:22–32.

    Article  CAS  Google Scholar 

  2. Banerjee K, Kumar S, Ross KA, Gautam S, Poelaert B, Nasser MW, et al. Emerging trends in the immunotherapy of pancreatic cancer. Cancer Lett. 2018;417:35–46.

    Article  CAS  Google Scholar 

  3. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science (New York). 2018;362:6411.

    Article  Google Scholar 

  4. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.

    Article  CAS  Google Scholar 

  5. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50.

    Article  CAS  Google Scholar 

  6. Guo Y, Chen Y, Liu X, Min JJ, Tan W, Zheng JH. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium. Cancer Lett. 2020;469:102–10.

    Article  CAS  Google Scholar 

  7. Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Singh AS, et al. Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. Biochem Biophys Res Commun. 2018;497(4):1055–61.

    Article  CAS  Google Scholar 

  8. Fritz SE, Henson MS, Greengard E, Winter AL, Stuebner KM, Yoon U, et al. A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma. Vet Med Sci. 2016;2(3):179–90.

    Article  CAS  Google Scholar 

  9. Zheng JH, Nguyen VH, Jiang SN, Park SH, Tan W, Hong SH, et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med. 2017;9(376):eaak9547.

  10. Eisenstein TK. Implications of Salmonella-induced nitric oxide (NO) for host defense and vaccines: NO, an antimicrobial, antitumor, immunosuppressive and immunoregulatory molecule. Microbes Infect. 2001;3(14–15):1223–31.

    Article  CAS  Google Scholar 

  11. Wang WK, Chen MC, Leong HF, Kuo YL, Kuo CY, Lee CH. Connexin 43 suppresses tumor angiogenesis by down-regulation of vascular endothelial growth factor via hypoxic-induced factor-1α. Int J Mol Sci. 2014;16(1):439–51.

    Article  Google Scholar 

  12. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002;8(12):1369–75.

    Article  CAS  Google Scholar 

  13. Zhou S, Gravekamp C, Bermudes D, Liu K. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018;18(12):727–43.

    Article  CAS  Google Scholar 

  14. Zhu K, Li G, Sun P, Wang R, Qian Y, Zhao X. In vitro and in vivo anti-cancer activities of Kuding tea (Ilex kudingcha C.J. Tseng) against oral cancer. Exp Therapeut Med. 2014;7(3):709–15.

    Article  Google Scholar 

  15. Song JL, Qian Y, Li GJ, Zhao X. Anti-inflammatory effects of kudingcha methanol extract (Ilex kudingcha C.J. Tseng) in dextran sulfate sodium-induced ulcerative colitis. Mol Med Rep. 2013;8(4):1256–62.

    Article  CAS  Google Scholar 

  16. Song C, Xie C, Zhou Z, Yu S, Fang N. Antidiabetic effect of an active components group from Ilex kudingcha and its chemical composition. Evid Based Complement Alternative Med. 2012;2012:423690.

    Google Scholar 

  17. Zheng J, Zhou H, Zhao Y, Lun Q, Liu B, Tu P. Triterpenoid-enriched extract of Ilex kudingcha inhibits aggregated LDL-induced lipid deposition in macrophages by downregulating low density lipoprotein receptor-related protein 1 (LRP1). J Funct Foods. 2015;18:643–52.

    Article  CAS  Google Scholar 

  18. Yin R, Li T, Tian JX, Xi P, Liu RH. Ursolic acid, a potential anticancer compound for breast cancer therapy. Crit Rev Food Sci Nutr. 2018;58(4):568–74.

    Article  CAS  Google Scholar 

  19. Ko EY, Moon A. Natural products for chemoprevention of breast Cancer. J Cancer Prev. 2015;20(4):223–31.

    Article  Google Scholar 

  20. Wu Y, Li Q, Liu Y, Li Y, Chen Y, Wu X, et al. Targeting hypoxia for sensitization of tumors to apoptosis enhancement through supramolecular biohybrid bacteria. Int J Pharm. 2021;605:120817.

    Article  CAS  Google Scholar 

  21. Baig B, Halim SA, Farrukh A, Greish Y, Amin A. Current status of nanomaterial-based treatment for hepatocellular carcinoma. Biomed Pharmacother. 2019;116:108852.

    Article  CAS  Google Scholar 

  22. El-Kharrag R, Amin A, Hisaindee S, Greish Y, Karam SM. Development of a therapeutic model of precancerous liver using crocin-coated magnetite nanoparticles. Int J Oncol. 2017;50(1):212–22.

    Article  CAS  Google Scholar 

  23. Xie Y, Mu C, Kazybay B, Sun Q, Kutzhanova A, Nazarbek G, et al. Network pharmacology and experimental investigation of Rhizoma polygonati extract targeted kinase with herbzyme activity for potent drug delivery. Drug Delivery. 2021;28(1):2187–97.

    Article  CAS  Google Scholar 

  24. Zhu S, Wei L, Lin G, Tong Y, Zhang J, Jiang X, et al. Metabolic alterations induced by Kudingcha Lead to Cancer cell apoptosis and metastasis inhibition. Nutr Cancer. 2020;72(4):696–707.

    Article  CAS  Google Scholar 

  25. Rawat L, Nayak V. Ursolic acid disturbs ROS homeostasis and regulates survival-associated gene expression to induce apoptosis in intestinal cancer cells. Toxicol Res. 2021;10(3):369–75.

    Article  Google Scholar 

  26. Zhang Q, Lu S, Li T, Yu L, Zhang Y, Zeng H, et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer Res. 2019;38(1):173.

    Article  Google Scholar 

  27. Zhou F, Liu F, Liu J, He YL, Zhou QM, Guo L, et al. Stachydrine promotes angiogenesis by regulating the VEGFR2/MEK/ERK and mitochondrial-mediated apoptosis signaling pathways in human umbilical vein endothelial cells. Biomed Pharmacother. 2020;131:110724.

    Article  CAS  Google Scholar 

  28. Wang W, Liu Y, You L, Sun M, Qu C, Dong X, et al. Inhibitory effects of Paris saponin I, II, VI and VII on HUVEC cells through regulation of VEGFR2, PI3K/AKT/mTOR, Src/eNOS, PLCγ/ERK/MERK, and JAK2-STAT3 pathways. Biomed Pharmacother. 2020;131:110750.

    Article  CAS  Google Scholar 

  29. Song F, Hu B, Cheng JW, Sun YF, Zhou KQ, Wang PX, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020;11(7):573.

    Article  CAS  Google Scholar 

  30. Li B, Zhang Y, Yin R, Zhong W, Chen R, Yan J. Activating CD137 signaling promotes sprouting angiogenesis via increased VEGFA secretion and the VEGFR2/Akt/eNOS pathway. Mediat Inflamm. 2020;2020:1649453.

    Google Scholar 

  31. Tanaka M, Nakamura S, Maekawa M, Higashiyama S, Hara H. ANKFY1 is essential for retinal endothelial cell proliferation and migration via VEGFR2/Akt/eNOS pathway. Biochem Biophys Res Commun. 2020;533(4):1406–12.

    Article  CAS  Google Scholar 

  32. Juaid N, Amin A, Abdalla A, Reese K, Alamri Z, Moulay M, et al. Anti-hepatocellular carcinoma biomolecules: molecular targets insights. Int J Mol Sci. 2021;22(19):10774.

  33. Abdalla A, Murali C, Amin A. Safranal inhibits angiogenesis via targeting HIF-1α/VEGF machinery: in vitro and ex vivo insights. Front Oncol. 2021;11:789172.

    Article  Google Scholar 

  34. Tan W, Duong MT, Zuo C, Qin Y, Zhang Y, Guo Y, et al. Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium. Mol Ther. 2022;30(2):662–71.

    Article  CAS  Google Scholar 

  35. Gurbatri CR, Lia I, Vincent R, Coker C, Castro S, Treuting PM, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020;12(530):eaax0876.

  36. Canale FP, Basso C, Antonini G, Perotti M, Li N, Sokolovska A, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature. 2021;598(7882):662–6.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Authors wish to thank Guomin Liu for his excellent technical assistance.

Funding

X. D. L. was supported by the Hainan Province Science and Technology Special Fund, China (ZDYF2022SHFZ041) and the Natural Science Foundation of Hainan Province, China (NO. 821RC529). S. N. J. was supported by the Natural Science Foundation of China (NO. 81960556). L. H. P. was supported by the Natural Science Foundation of Hainan Province, China (NO. 821RC584).

Author information

Author notes

  1. Haixia Xu and Linghua Piao contributed equally to this work.

Authors and Affiliations

  1. School of Life Sciences, Hainan University, No. 58 Renmin Avenue, Haikou, 570228, China

    Haixia Xu & Xiande Liu

  2. Department of Physiology, Hainan Medical University, Haikou, China

    Linghua Piao

  3. Department of Nuclear Medicine, Central South University, Xiangya School of Medicine, Affiliated Haikou Hospital, No. 43 Renmin Avenue, Haikou, 570208, China

    Sheng-nan Jiang

Authors
  1. Haixia Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linghua Piao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiande Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sheng-nan Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H. X. X performed investigation, data analysis, and generated the Figs. L. H. P. performed investigation and wrote the manuscript. X. D. L. designed experiments and wrote the manuscript. S. N. J designed experiments and wrote the manuscript. The author(s) read and approved the final manuscript.

Corresponding authors

Correspondence to Xiande Liu or Sheng-nan Jiang.

Ethics declarations

Ethics approval and consent to participate

All the procedures and protocols involving plant were conducted in conformity with WHO Guidelines on Good Agricultural and Harvesting Practices (GAP) for Medicinal Plants (2003) and approved by the Ethic Committee from Hainan University (Haikou, Hainan, China).

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

12906_2022_3612_MOESM1_ESM.pdf

Additional file 1.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, H., Piao, L., Liu, X. et al. Ursolic acid-enriched kudingcha extract enhances the antitumor activity of bacteria-mediated cancer immunotherapy. BMC Complement Med Ther 22, 123 (2022). https://doi.org/10.1186/s12906-022-03612-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-022-03612-2

Keywords

  • BCI
  • Ursolic acid-enriched KDCE
  • Antiangiogenesis
  • VEGFR2

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us